by Buck Institute

Astera Institute and Buck Institute announce $70 million collaboration to redefine the field of research on aging

The Rejuvenome Project is a first of its kind study seeking to fully characterize aging and validate optimal longevity intervention combinations for extending lifespan

The Buck Institute and the Astera Institute today announced a comprehensive, multi-omics study of the biological effects of longevity interventions. Through a series of large-scale lifespan studies in genetically diverse mice, researchers will test interventions, both alone and in combination, known or suspected to impede or reverse aging and extend longevity.

The work aims to create an open and comprehensive dataset to better understand the biology of aging and the underlying mechanisms of how to potentially impede the aging process. This dataset, which will be freely accessible to the research and drug discovery communities, will provide the most complete picture of the impact of aging interventions in mice across multiple biomarkers and clinically relevant phenotypes. Leading scientists and thought leaders across the field will participate in the selection and design of the interventions.

Research on aging is at a critical inflection point, with breakthroughs in basic science and multiple compounds being tested in clinical trials. While the field is starting to have tools and treatments that target the biology of aging and improve health, a deep and fundamental understanding of how they work, and the models used to validate such findings, is still lacking. Further, because of vision, funding constraints, infrastructure limitations and other impediments, smaller projects are conducted independently of each other and there is little to no research into combination therapies, even though this will likely be the only avenue to achieving meaningful results.

“The Rejuvenome Project was launched to target these bottlenecks,” says Nicholas Schaum, PhD, Scientific Director of Rejuvenome. “We hope to do that by characterizing treatments and regimens, both established and newly invented, for which we have reason to believe improve health and longevity.”

“The breadth and depth of this project centered around an unprecedentedly extensive and deep whole-body functional and multi-omic assay panel has the potential to redefine scientific understanding of how to best intervene in the aging process,” says Eric Verdin, MD, President and CEO of the Buck Institute. “We are delighted to partner with Astera on this very significant work.”

The Rejuvenome Project is expected to take approximately seven years to complete. All wet lab operations will be centered at the Buck while the dry lab computational aspects of the project will reside at the Astera Institute in Berkeley. “The Rejuvenome is the quintessential moonshot project in longevity,” says Astera’s founder Jed McCaleb. “If we are successful it will provide the most complete picture ever of how best to intervene in aging and will produce powerful new avenues for drug development.”


About the Astera Institute:

The Astera Institute was established by entrepreneur and philanthropist Jed McCaleb. The Institute is a 501(c)(3) nonprofit dedicated to developing high leverage technologies that can lead to massive returns for humanity. Astera’s  high-impact potential derives from housing moonshots and novel scientific research that have no other natural home in today’s research and development landscape. Astera focuses on longevity, Artificial General Intelligence, metascience, and frontier technology. https://astera.org/about/

Science is showing that while chronological aging is inevitable, biological aging is malleable. There's a part of it that you can fight, and we are getting closer and closer to winning that fight.

Eric Verdin, MD, Buck Institute President and CEO

Support the Buck

We rely on donations to support the science that we believe will add years to people's lifespan and decades to their healthspan.